Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02191410
Other study ID # N2014045
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date January 2019
Est. completion date June 2020

Study information

Verified date May 2018
Source Dammam University
Contact Mohamed R El Tahan, MD
Phone +966 13 865 1193
Email mohamedrefaateltahan@yahoo.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The stroke volume variation (SVV), measured using the Vigileo-FloTrac system (Edwards Lifescience, Irvine, CA), has been shown to able to predict fluid responsiveness during one-lung ventilation (OLV) in patients undergoing pulmonary lobectomy (sensitivity: 82.4%, specificity: 92.3%).1 Many parameters such as tidal volume (TV),1-2 positive end-expiratory pressure (PEEP),3 respiratory rate (RR), 4 chest and lung compliance,5 heart rate and rhythm, and ventricular function and afterload,6-7 all have been documented to have effects on the SVV.

SVV is calculated as the variation of beat-to-beat SV from the mean value during the most recent 20 seconds of data: SVV = (SVmax − SVmin)/SVmean, where SVmax, SVmin, and SVmean are, respectively, the maximum, minimum, and mean SV determined by the system.

SVV may not be sufficiently sensitive to predict fluid responsiveness in patients with right ventricular (RV) dysfunction due to concomitant increases in RV afterload, that lead to a decrease in preload variation and subsequent inaccuracy in SVV measurements.8

OLV may increase airway pressure, resulting in increases in the RV afterload, end-diastolic volume, and stroke work index, thus impeding RV function.9-11The increases in the right ventricular afterload may exaggerate the cyclic variation in stroke volume.12

In the authors' previous study,9 they found that the high-frequency positive-pressure ventilation (HFPPV) was superior to continuous positive-airway pressure (CPAP) for OLV, resulting in significantly higher RV ejection fraction, lower RV afterload and higher arterial oxygenation, whereas the former limiting the adequate operative field visualization during video-assisted thoracoscopic surgery (VATS).13

The effects of the nondependent lung ventilation with HFPPV and CPAP on the SVV and fluid responsiveness during OLV has not yet been studied.


Description:

In all patients, standard monitors, and state and response entropy (SE and RE, respectively) based-depth of anesthesia will be applied. Normothermia will be maintained by using forced-air warming blankets. Anesthetic technique will be standardized in all studied patients. Anesthesiologists who give the anesthetic will be not involved in the collection of outcome data. General anesthesia will be induced with propofol (2-3 mg kg-1) and fentanyl (2-3 µg kg-1) to achieve a SE value less than 50 and the difference between RE and SE less than 10.

Cisatracurium (0.2mg kg-1) will be administered to facilitate the placement of a left-sided double-lumen tube, and the correct position of its tip will be confirmed with a fiberoptic bronchoscope.

Anesthesia will be maintained with 0.7 to 1.5 minimum alveolar concentration of sevoflurane and 0.5 µg kg-1 increments of fentanyl to maintain the SE values less than 50 and the difference between RE and SE less than 10. Suppression of the second twitch in train-of-four stimulation of the ulnar nerve will be maintained with 0.03mg kg-1 increments of cisatracurium.

The radial artery will be catheterized. Cardiac index (CI) and SVV will be measured by using a Vigileo-FloTrac system (v1.14, Edwards Lifescience, Irvine, CA).

Patients' two lungs (TLV) will be mechanically ventilated with a pressure-controlled ventilation mode, a fraction of inspired oxygen (FiO2) of 0.4 in air, TV of 8 mL kg-1 (predicted body weight (PBW)), inspiratory to expiratory (I: E) ratio of 1:2.5 and PEEP of 5 cm H2O, fresh gas flow (FGF) of 1.5-1.7 L min-1, and RR adjusted to achieve a PaCO2 of 35-45 mm Hg.

During OLV,TV, FiO2, I: E ratio, PEEP, FGF, and RR, will be maintained as during TLV and the lumen of the nondependent lung will be left open to air.

After thoracostomy, patients will be randomly allocated to one of two by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code.

The patient's nondependent lung during OLV will be ventilated with a CPAP of 2 cm H2O or HFPPV as randomized.

All patients will receive lactated Ringer's solution at 2mL kg-1 h-1 during surgery. The capability of SVV to predict fluid responsiveness during CPAP or HFPPV will be assessed at 30 min after randomization.

Hemodynamic control will be standardized according to the authors' protocol. If MAP dropped down to 60 mmHg, 250 mL of plasma protein fraction 5% will be administered, and, if this will not enough, repeated doses of intravenous of ephedrine 5 mg or phenylephrine 100 µg, will be administered to maintain urine output to be equal or greater than 0.5 mL kg-1 hour-1. A hemoglobin concentration of 8 g dL-1 or greater will be compensated with red blood cell concentrates.

An independent investigator blinded to the study groups who will not be involved in the patients' management collected the data.

As in previous studies,14-15 the sample size is determined by considering that an area under the ROC curve ≥ 0.8 is clinically reliable to predict fluid responsiveness. To detect a 0.3 difference from the null hypothesis of 0.5, 28 patients will be required in each group with a type-I error of 0.05 and a power of 80% under the ROC curve, assuming equal number of responders and non-responders. To compensate for a dropout rate of 10%, 31 patients will be included in each group.

Normal distributions of data will be assessed using Kolmogorov-Smirnov test. Student's paired t-test or the Wilcoxon signed-rank test will be used to compare hemodynamic variables obtained at the 2 time points (T0, T1) before and after volume expansion. Hemodynamic variables between responders and non-responders within the group at each time point will be compared using Student independent t-test or Mann-Whitney U-test where appropriate. The x2 test will be used when indicated. The Pearson rank method tests linear correlations between SVV before volume loading (T0) and absolute changes in SVV (∆SVV) and percentage change in SVI (∆SVI) after volume. The responders are defined as those patients who demonstrates a ≥ 15% increase in CI after volume expansion between T0 and T1.16 A ROC curve for each variable will be generated and an area under the ROC curve will be calculated. Using this analysis, the optimal threshold value, sensitivity and specificity of SVV during each study intervention could be determined. The ROC curves will be compared using the DeLong test. Data will be expressed as mean ± SD, medians [IQR], or number (%). A value of p< 0.05 is considered to be statistically significant.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 62
Est. completion date June 2020
Est. primary completion date April 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- American Society of Anesthesiologists physical class of II to III

- Duration of OLV is expected to exceed 1.5 hours

Exclusion Criteria:

- New York Heart Association class > II

- Right ventricular dysfunction

- Pulmonary hypertension

- valvular heart disease

- intracardiac shunts

- Any cardiac rhythm other than sinus

- Hypertension

- Diabetes mellitus

- Renal dysfunction

- Hepatic dysfunction

- Pregnancy

- Body mass index >35 kg m-2

- Peripheral arterial occlusive disease

- preoperative administration of inotropic medications

Study Design


Intervention

Procedure:
High Frequency Positive Pressure Ventilation
TV 2 mL kg-1 PBW, I:E ratio > 0.3, RR 60 breaths min-1 and a FGF of < 2 L min-1, using a second identical ventilator with low compliant internal circuit
Continuous Positive Airway Pressure
CPAP of 2 cm H2O

Locations

Country Name City State
Saudi Arabia King Fahd Hospital of the University Khobar Eastern

Sponsors (1)

Lead Sponsor Collaborator
Dammam University

Country where clinical trial is conducted

Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fluid responsiveness To explore the ability of SVV to predict fluid responsiveness with ROC plots 5 min after volume loading
Secondary Heart rate 5 min before volume loading, 5 min after volume loading
Secondary Stroke volume variation 5 min before volume loading, 5 min after volume loading
Secondary Mean blood pressure 5 min before volume loading, 5 min after volume loading
Secondary Cardiac index 5 min before volume loading, 5 min after volume loading
Secondary Stroke Volume Index 5 min before volume loading, 5 min after volume loading
Secondary Airway pressures 5 min before volume loading, 5 min after volume loading
Secondary Lung Compliance 5 min before volume loading, 5 min after volume loading
See also
  Status Clinical Trial Phase
Completed NCT02217423 - Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy N/A
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Completed NCT01679301 - Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator N/A
Terminated NCT00966823 - Fetal Tracheal Balloon Study in Diaphragmatic Hernia Phase 2
Completed NCT00139152 - Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair Phase 4
Completed NCT00052052 - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT00013949 - Cardiovascular Vulnerability to Particulate Exposure N/A
Recruiting NCT02963467 - Effect of Smoking on Ventilation-Perfusion Ratio N/A
Recruiting NCT02965300 - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis N/A
Enrolling by invitation NCT02946658 - Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders Phase 1/Phase 2
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Completed NCT01952002 - Clinical Safety for the Inspiratory Muscle Training N/A
Completed NCT01735526 - Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation N/A
Recruiting NCT01450644 - Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease Phase 2
Completed NCT01153321 - Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Completed NCT01215279 - AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD) Phase 2
Completed NCT00837681 - Pulmonary Complications of Hematopoietic Stem Cell Transplantation N/A
Completed NCT02055222 - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Completed NCT01222442 - To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart Phase 1